Ad hoc-Mitteilungen
• 07:05 Medacta Group • 12.07.20 PREMIA FOODS AS PREMIA FOODS ORD SHS • 10.07.20 Volta Finance • 10.07.20 Erytech Pharma • 10.07.20 AEVIS VICTORIA NA • 10.07.20 Agfa-Gevaert • 10.07.20 Hesse Newman Capital • 10.07.20 Volta Finance • 10.07.20 DBV Technologies • 10.07.20 BASF •
  • Startseite
  • Aktien
  • Nektar Therapeutics Aktie
  • News

    • Nektar Therapeutics News

    21,385 € 0,00% +0,00 €
    10.07.20 08:00:19 München | Mehr Kurse »
    WKN: 165417
    ISIN: US6402681083
    US-Symbol: NKTR
    Typ: Aktie
    Jetzt für 0€ handeln

    Nektar Therapeutics News

      
    < Zurück < Zurück
    von 10
    Weiter > Weiter >
    < Zurück < Zurück
    von 10
    Weiter > Weiter >
    04.06.20 - PR Newswire
    Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
    Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020) /* Style Definitions */ spa...
    29.05.20 - PR Newswire
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
    Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) /* Style Definitions */ span...
    22.05.20 - PR Newswire
    Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-​Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
    Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-​Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal /* Style ...
    07.05.20 - PR Newswire
    Nektar Therapeutics Reports First Quarter 2020 Financial Results
    Nektar Therapeutics Reports First Quarter 2020 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.pr...
    28.04.20 - PR Newswire
    Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
    Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets /* Style Definitions */ span.prnews_span { fo...
    28.02.20 - PR Newswire
    Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
    Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-...
    27.02.20 - PR Newswire
    Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
    Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a ...
    18.02.20 - PR Newswire
    Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
    Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets /* Style ...
    03.02.20 - PR Newswire
    Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-​oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications
    Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-​oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications /* Style ...
    24.01.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR /* Style Definitions */ span.prnews_span { font-size:8pt; fo...
    14.01.20 - PR Newswire
    Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
    Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { ...
    13.01.20 - PR Newswire
    Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?
    Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA? /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews...
    07.01.20 - PR Newswire
    Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
    Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA /* Style Definitions */ span.prnew...
    17.12.19 - PR Newswire
    Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
    Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } ...
    09.12.19 - PR Newswire
    Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
    Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting /* Style ...
    03.12.19 - PR Newswire
    Nektar Appoints John Northcott as Chief Commercial Officer
    Nektar Appoints John Northcott as Chief Commercial Officer /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_...
    13.11.19 - PR Newswire
    Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
    Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { ...
    10.11.19 - PR Newswire
    Nektar Therapeutics Presents Data from First-​in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
    Nektar Therapeutics Presents Data from First-​in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of ...
    09.11.19 - PR Newswire
    Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-​Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-​Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting /* ...
    06.11.19 - PR Newswire
    Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
    Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019 /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color ...
    01.11.19 - PR Newswire
    Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting
    Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting ...
    30.10.19 - PR Newswire
    Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets
    Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets /* Style Definitions */ span.prnew...
    16.10.19 - PR Newswire
    Nektar Therapeutics Announces Initiation of First-​in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-​Hodgkin Lymphoma or Multiple Myeloma
    Nektar Therapeutics Announces Initiation of First-​in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-​Hodgkin Lymphoma ...
    07.10.19 - PR Newswire
    Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
    Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis /* ...
    04.10.19 - ARIVA.DE
    Aktienmarkt: S&P 500 heute leicht im Plus
    Für den S&P 500-Index verlief der bisherige Aktienhandel heute positiv. Das Börsenbarometer steigt kräftig um 1,27 Prozent.
    04.10.19 - ARIVA.DE
    Nektar Therapeutics-​Aktie heute am Aktienmarkt gefragt
    Die Nektar Therapeutics-​Aktie notiert am Freitag etwas fester. Die Aktie notiert derzeit bei 18,97 US-Dollar.
    04.10.19 - ARIVA.DE
    Aktien USA: S&P 500 profitiert zur Stunde leicht
    Die Aktie von Skyworks Solutions ist aktuell der größte Gewinner im S&P 500-Index. Konsequenz Das Kursbarometer klettert um 0,93 Prozent.
    04.10.19 - ARIVA.DE
    Impulse fehlen – S&P 500 fast unverändert
    Die Aktie von Skyworks Solutions ist gegenwärtig der größte Gewinner im S&P 500. Das Kursbarometer gewinnt 41 Punkte.
    02.10.19 - ARIVA.DE
    S&P 500 verliert leicht: Heute 89 Punkte weniger
    Leichte Kurs­verluste verzeichnet zur Stunde der S&P 500. Der Index sinkt leicht um 1,64 Prozent.
    02.10.19 - ARIVA.DE
    Nektar Therapeutics-​Aktie büßt 4,94 Prozent ein
    Am US-​amerikanischen Aktienmarkt liegt der Anteilsschein von Nektar Therapeutics aktuell im Minus. Der jüngste Kurs betrug 17,52 US-Dollar.
    02.10.19 - PR Newswire
    Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Nektar Therapeutics Announces Five Abstracts Accepted for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting /* Style Definitions */ span.prne...
    01.10.19 - PR Newswire
    Nektar Announces Key Executive Promotions
    Nektar Announces Key Executive Promotions /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; f...
    26.09.19 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR /* Style Definitions */ span.prnews_span { font-size:8pt; fon...
    26.09.19 - ARIVA.DE
    Kaum Impulse für den S&P 500
    Kurs­verluste und Kursgewinn halten sich beim S&P 500 derzeit in etwa die Waage. Das Börsenbarometer gewinnt 15 Punkte.
    26.09.19 - PR Newswire
    Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600
    Las Vegas Sands Set to Join S&P 500; Nektar Therapeutics to Join S&P MidCap 400; The Pennant Group to Join S&P SmallCap 600 /* Style Definitions */ span.prnews_span { font...
    26.09.19 - ARIVA.DE
    Nektar Therapeutics-​Aktie an der Börse auf der Verliererseite: Börsenkurs fällt deutlich
    An der US-​amerikanischen Börse fällt gegenwärtig die Aktie von Nektar Therapeutics negativ auf. Der Titel verliert deutlich an Wert.
    26.09.19 - PR Newswire
    Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-​Negative Breast Cancer Patients at the 2019 CRI-​CIMT-EATI-AACR International Cancer Immunotherapy Conference
    Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-​Negative Breast Cancer Patients at the 2019 CRI-​CIMT-EATI-AACR ...
    24.09.19 - ARIVA.DE
    Aktienmarkt: S&P 500 tendiert zur Stunde leichter
    Für den S&P 500-Index brachte der bisherige Aktienhandel heute leichte Verluste. Das Aktienbarometer rutscht um 1,35 Prozent ab.
    24.09.19 - ARIVA.DE
    Investoren meiden heute das Wertpapier von Nektar Therapeutics: Kurs gibt deutlich nach
    Die Aktie von Nektar Therapeutics zählt am Dienstag zu den großen Verlierern am Aktienmarkt. Der Kurs der Aktie sackt kräftig ab.
    23.09.19 - PR Newswire
    Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-​CIMT-EATI-AACR Cancer Immunotherapy Conference
    Nektar Therapeutics Announces Abstract Accepted for Presentation at the 5th CRI-​CIMT-EATI-AACR Cancer Immunotherapy Conference /* Style Definitions */ span.prnews_span { f...
    18.09.19 - ARIVA.DE
    S&P 500 aktuell ohne klare Richtung
    Die Aktie von Kla-​Tencor ist derzeit der größte Gewinner im S&P 500. Zur Stunde liegt das Börsenbarometer mit 0,39 Prozent ganz leicht im Minus.
    12.09.19 - PR Newswire
    NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics
    NKTR CLASS ACTION ALERT: Bernstein Liebhard LLP Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics /* Style Definitions */ span.prnews_...
    10.09.19 - ARIVA.DE
    S&P 500 heute kaum bewegt
    Die Aktie von Nektar Therapeutics ist zur Stunde der größte Gewinner im S&P 500. Das Börsenbarometer verliert 0,39 Prozent auf 2.968 Punkte.
    10.09.19 - ARIVA.DE
    S&P 500 tritt auf der Stelle
    Die Aktie von Nektar Therapeutics ist derzeit der größte Gewinner im S&P 500. Das Börsenbarometer verliert 14 Punkte.
    10.09.19 - ARIVA.DE
    Große Kurs­gewinne für die Nektar Therapeutics-​Aktie
    Grund zur Freude haben Anleger, die in die Nektar Therapeutics-​Aktie investiert haben: Der Kurs des Anteilsscheins legt kräftig zu.
    10.09.19 - ARIVA.DE
    Aktienmarkt: S&P 500 fehlen die Impulse
    An der Börse findet der S&P 500 gegenwärtig keine klare Richtung. Das Börsenbarometer gibt derzeit lediglich 0,46 Prozent ab.
    03.09.19 - PR Newswire
    Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR
    Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR /* Style Definitions */ span.prnews_span { font-size:8pt; font-...
    03.09.19 - ARIVA.DE
    Nektar Therapeutics-​Aktie mit Kursverlusten
    Im Minus liegt gegenwärtig das Wertpapier von Nektar Therapeutics. Der jüngste Kurs betrug 16,74 US-Dollar.
    30.08.19 - PR Newswire
    LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
    LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm /* Style Definitions */ span.prnews_span { font-size:8pt; font-​family:"Arial"; color:black; } a....
    29.08.19 - PR Newswire
    ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR
    ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR /* Style Definitions */ span.prnews_span { font-...
    < Zurück < Zurück
    von 10
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    05:00 Uhr
    IG Trading Talk: "Markets up on stimulus. Earnings season ahead, drop by 44%? Banks, FANG stocks"
    Investors turn their attention to earnings season this week. Major banks are among the first to report. ... Mehr »